

REMARKS

After entering these amendments, Claims 1 and 3-9 will be pending. Claims 1 and 8 have been amended. Claim 2 has been canceled.

THE REJECTIONS UNDER 35 U.S.C. §112:

Claims 8 and 9 were rejected under 35 U.S.C §112, first paragraph, in the June 28, 2006 Office Action and the Examiner has maintained this rejection as applied to “fragility an[d] or age related functional decline.” (September 18, 2006 Advisory Action, Page 2). Applicants traverse. Applicants have amended Claim 8 and thereby Claim 9 to delete “frailty or age-related functional decline”. Applicants, therefore, respectfully request the Examiner withdraw this rejection as it is now moot.

CLAIM OBJECTIONS

Claims 1 and 3-7 are objected to because there appears to be a typographical error in the definition of variable Y. (September 18, 2006 Advisory Action, Page 3). Applicants thank the Examiner for bringing this inadvertent typographical error to their attention. Applicants have amended Claim 1 and thereby Claim 3-7 to correct the definition of variable Y to recite the following:

Y is selected from the group consisting of O, NR₄, NOR₄, S, and CH₂;


Applicants, therefore, respectfully request the Examiner withdraw this objection as it is now moot.

CONCLUSION

No fee is believed due for the filing of this Amendment; however, should any fee be found to be due please charge said fee to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company. In view of the foregoing, applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Samuel G. Duncan, Jr., Ph.D.
Attorney for Applicant
Reg. No. 46,675
Phone: 609-252-6270
Date: September 27, 2006